title: Payers move slowly on test coverage decisions.
abstract: Formulary decisions might be considered a snap when compared to decisions about coverage of a genetic test. The presence - or lack - of credible data to demonstrate cost-effectiveness is usually the touchstone.
authors: Bob
authors: B
authors: Carlson